Background & aim: The addition of prebiotics to infant formula modifies the composition of intestinal microflora. Aim of the study was to test the hypothesis that prebiotics reduce the incidence of intestinal and respiratory infections in healthy infants.
Introduction
Infectious diseases are generally less frequent in breast-fed infants than in formula-fed infants 1, 2 and this may be due in part to the peculiar pattern of microbial colonization typical of mother's milk. 3, 4 Prebiotics are defined as ''non-digestible food ingredients that beneficially affect the host by selectively stimulating the growth and/or activity of a limited number of bacterial species in the colon''. 5 Their addition to infant formulas is expected to exert beneficial effects on health. However, although prebiotics increase the load of lactobacilli and bifidobacteria and make intestinal microflora of formula-fed infants similar to that observed in breastfed infants, [6] [7] [8] [9] it is not clear whether this translates into clinically relevant effects. The intestinal microbiota of breast-fed infants is generally dominated by bifidobacteria and lactic acid bacteria, whereas the intestinal microecology of formula-fed infants is more similar to that of adults in that it contains heavier loads of Bacteroides, Clostridia and Enterobacteriaceae. 3, 4, 10 It is now becoming clear that the intestinal microflora is in a symbiotic relationship with the host and may drive immune imprinting in the early life. [11] [12] [13] Therefore dietary components that are capable of modifying the composition of intestinal microbiota may affect the postnatal development of the immune system, leading to clinical effects. A link between changes in intestinal microflora and prevention of diseases has been shown for probiotics. Administration of selected probiotics has been associated with the prevention of gastrointestinal infections 14 and with a reduced incidence of respiratory tract infections. 15 We recently reported that administration of Lactobacillus GG reduced the incidence of pulmonary exacerbations and of hospital admissions in cystic fibrosis patients. 16 For prebiotics there is virtually no evidence of clinical effects. Despite the wealth of evidence that a galacto/fructo-oligosaccharide (GOS/FOS) mixture positively affects the intestinal microflora, it is not yet clear whether this results in clinically relevant effects. Recently it was shown that term infants fed with a formula supplemented with a prebiotic mixture containing polydextrose, oligosaccharides and lactulose had growth and stool characteristics more similar to those of breast-fed infants compared with infants fed with a standard formula. 17 Very recently, a formula supplemented with the GOS/FOS mixture significantly reduced the development of atopic dermatitis in high risk infants. 18 The same prebiotic mixture reduced episodes of all types of infections in infants at risk of atopy. 19 We designed this prospective, casecontrolled, randomized study to test the hypothesis that prebiotics may have clinically relevant effects in a normal infant population.
To this aim, we investigated whether early administration of a GOS/ FOS-containing formula affected the risk of intestinal and/or respiratory infections in infants.
Patients and methods

Study design
A multicenter, prospective, randomized, placebo-controlled open trial with two intervention groups was carried out with the collaboration of family pediatricians. Due to the pilot nature of the study, and in line with the proposal by participating family pediatricians, an open-study design was applied. Healthy infants aged between 15 and 120 days were enrolled by 38 pediatric practitioners in 7 Italian regions, after informed consent was obtained from the parents. The inclusion criteria were gestational age between 37 and 42 weeks, birth weight greater than 2500 g, and introduction of formula feeding after at least 15 days of exclusive feeding with maternal milk. Exclusion criteria were twins, clinically significant illness of the mother, congenital immunodeficiency, any chronic or progressive diseases, proven or suspected allergy, and previous intake of pro-or prebiotics. Infants were enrolled when formula milk was introduced and this was always done independently from the study.
Eligible infants were randomly assigned to receive either a standard infant formula or a prebiotic-supplemented formula for 12 months. The two formulas were identical except for the addition of a mixture of GOS/FOS in a ratio of 9:1. The concentration of GOS/ FOS was 0.4 g/100 ml and the two formulas showed a similar osmolality (280 mOsm/l and 290 mOsm/l, respectively). Randomization was conducted using a random numbers table with a block design for groups of 10 infants.
Informed consent was obtained from the parents of all enrolled children. The study was approved by the local ethics committee.
Study end points
Primary outcome measures were incidence of acute diarrhea, incidence of upper and lower respiratory tract infections, and number of antibiotic courses prescribed for respiratory infections. Acute diarrhea was defined as a stool pattern with 3 or more loose or watery stools/day lasting at least for 3 days. Otitis, pharyngitis, laryngitis, tracheitis and bronchitis were considered as upper respiratory tract infections (URTIs). The diagnosis was made by the family pediatrician based on specific symptoms, with or without fever. All episodes of respiratory infections were recorded during a follow-up of 12 months. Antibiotic courses were also recorded. Secondary outcome measures, used to assess nutritional adequacy, were weight, length and head circumference gain. All the parameters were recorded at enrolment and were monitored at 3, 6, 9 and 12 months after enrolment.
Study protocol
Each infant underwent the routine evaluation by pediatrician and was monitored for 12 months after enrolment. Every 3 months, the routine visit included a medical examination and measurements of weight, length and head circumference by standard methods. 20 Further clinical assessment was performed in case of gastrointestinal or respiratory symptoms. Primary and secondary outcome measures were recorded on a specific case-report form.
Statistical analysis
The sample sizes required to detect a reduction of 30% in the incidence of acute diarrhea and of URTI, at a 5% significance level and with 85% of power, included 150 infants for acute diarrhea and 200 infants for URTI per group. These numbers were based on the expected incidence of 0.5 episodes/year of acute diarrhea in children up to 3 years of age and of 5 episodes/year of URTI in children up to 4 years of age. A total of 342 children were enrolled in the study (169 in GOS/FOS group and 173 in the control group). A total of 201 children completed the study (96 in GOS/FOS group and 105 in the control group). The drop out rate at the different follow-up times was compared using the Kaplan-Meier method. Log-Rank test showed no significant differences (p ¼ 0.212). In order to test a Missing Completely At Random (MCAR) mechanism, at each time (3, 6, 9, 12 months), the growth parameters of the lost to follow-up children, taken at the previous follow-up times (respectively, at the enrolment time and at 3,6 and 9 months), were compared with that of the infants who continued the study, using the t-test for independent samples and no significant differences were detected (p [ 0.05, data not shown). The lack of any differences in the drop out pattern of the two groups allowed us to consider in the statistical analysis of the outcome variables, only those children who effectively complete the study, thus we perform a per protocol analysis. However, in order to measure the effective power of the statistical procedures (based on the reduced sample size), a postexperimental power analysis was performed. The power curves were evaluated by using the upper bound of the confidence intervals (with a confidence level of 95%) for the standard deviation of each outcome variable, assuming that the data were normally distributed.
The results of the two formula groups were evaluated with the t-test for anthropometric measurements (results expressed as means AE SD) and for the incidence of acute diarrhea and URTI (results expressed as means AE SEM). We used the c 2 analysis to compare the proportion of children with URTI and with acute diarrhea, as well as to compare the rates of antibiotic use in the two groups. Value of p < 0.05 was considered significant. Fig. 1 shows the flow chart of enrolled children throughout the study. A total of 349 infants were assessed for eligibility, 7 were excluded (2 were born at 36 weeks of gestation, 2 were twins, and 3 were small for gestational age). Thus, the study population consisted of 342 infants who were randomly assigned to the GOS/FOS formula (n ¼ 169 infants) or to the control formula (n ¼ 173 infants). At enrolment, there were no differences between the two groups in terms of gender, gestational age, mean weight at birth, mean duration of breastfeeding, mean age, weight, length, head circumference ( Table 1 ). The relative number of children lost to follow-up was similar in the two groups. Seventy-three infants in the GOS/ FOS group and 68 in the control group failed to complete the study because of non-compliance and protocol violation (such as early introduction of weaning or probiotic assumption) or because of incomplete data, and a total of 201 infants completed the study. During the first 3 months of the study, 3 infants in the GOS/FOS group and 2 in the standard formula group developed cow's milk protein intolerance (CMPI). There was no evidence of a cause-effect relationship between the introduction of enriched formula and cow's milk protein intolerance.
Results
Baseline features of infants enrolled
Safety and tolerance
There was no report of major side effects. The stool pattern of children receiving prebiotics was generally characterized by softer but not diarrheic stools and in no case was the prebiotic formula withdrawn.
Primary outcome measures
As shown in Fig. 2 , the rate of diarrheal episode/child was significantly lower in children receiving the GOS/FOS formula than in controls (0.12 AE 0.04 vs. 0.29 AE 0.05 episodes/child/12 months; C.I. 95% mean difference -0.3-0.03; p ¼ 0.015) (Fig. 2A) . In addition, the number of children with at least 1 episode of acute diarrhea was significantly lower in the GOS/FOS group 10/96 (10.4%) vs. 26/109 (23.8%); p ¼ 0.01, RR: 0.44; C.I. 95% RR: 0.22-0.86 (Fig. 2B) .
The number of episodes of URTI was lower in the GOS/FOS group, but the difference was not significant (p ¼ 0.4). The number of children with at least 1 episode of URTI was similar in the two groups. However, among the children with at least 1 episode of URTI, the number of children with recurrent URTI, defined as more than 3 episodes of URTI in 12 months, was lower in children fed with the GOS/FOS formula (17/60 vs. 29/65) and the difference was close to significance (p ¼ 0.06; Fig. 3A) .
Administration of prebiotics was associated with a lower number of antibiotic prescription. The mean rate of antibiotic courses prescribed for children fed with GOS/FOS was significantly lower compared to controls (1.03 AE 0.15 vs. 1.48 AE 0.16; p ¼ 0.038; C.I. 95% mean difference -0.88-0.02). Moreover, the percent of children receiving 2 or more antibiotic courses/year was Total assessed for eligibility n. 349
Randomized n. 342
Excluded = 7 No meeting inclusion criteria
Allocated to the GOS/FOS group n. 169
Allocated to the standard formula group n. 173
Lost to follow-up (poor compliance to the protocol) (n=30) Discontinued intervention (development of CMPI) (n=3) Lost to follow-up (poor compliance to the protocol) (n=26) Discontinued intervention (development of CMPI) (n=2)
Visit at 12 months (n.105) Visit at 12 months (n.96)
Completed, per protocol basis n. 201
Excluded from analysis for incomplete data or protocol violation n. 40
Excluded from analysis for incomplete data or protocol violation n. 40 Fig. 1 . Flow chart of children enrolled in the study. A total of 349 infants were assessed for eligibility; 342 infants were assigned randomly to the GOS/FOS formula (n ¼ 169 infants) or to the control formula (n ¼ 173 infants). (Fig. 3B) ). The latter finding is consistent with the observed reduced number of children with recurrent URTI in the GOS/FOS group. The number of lower respiratory tract infections was very low in both controls and GOS/FOS group (4 vs. 6 episodes, respectively) and no further evaluation was made.
Secondary outcome measures
Secondary outcome measures are shown in Fig. 4 . The average growth parameters (i.e., weight, length and head circumference) were within the normal ranges in both groups. However, the mean body weight was significantly increased at 3 and 6 months of follow-up, in the GOS/FOS formula group compared to the control group (p < 0.01), whereas it was similar in the two groups at 9 and 12 months of follow-up (Fig. 4A) . Mean body length was significantly greater in the GOS/FOS group at 3, 6, 9 and 12 months of follow-up than in controls (p < 0.05) (Fig. 4B) . Mean head circumference was similar in the two groups at 3, 6, 9 and 12 months of follow-up (data not shown).
Discussion
Prebiotic addition to infant formula is associated with increased costs compared with standard infant formula and it is therefore important to establish whether this intervention is associated with clinical effects.
The results of this study provide evidence of an association between the administration of prebiotics and clinical effects in healthy infants. The most convincing finding is the preventive effect exerted against intestinal infections. This was supported by the reduction of the total number of diarrheal episodes and of the number of children with at least 1 gastroenteritis episode in those receiving the enriched formula. In this context, it is noteworthy that probiotics have been found to give protection against acute gastroenteritis. 14 A less robust but even more interesting observation is the reduction of respiratory infections. Although the direct parameter was not significantly different between the two groups, all outcome measures enclosed in the evaluation pointed toward a decreased incidence of respiratory infections in the GOS/FOS group. The protective effect by prebiotics was further supported by the significant reduction of antibiotic courses in infants receiving the enriched formula.
A preventive effect by modified intestinal microflora against non-intestinal infections is not entirely new. We and others have observed a lower incidence of respiratory infections after the administration of probiotics in children at increased risk of respiratory infections, 15, 16 such as those with cystic fibrosis. Recently it has been published that the administration of GOS/FOS enriched formula protects formula-fed infant, at high risk of atopy, against infections during the first 6 months of life.
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Infections of the intestinal or respiratory tract, although of mild degree in the vast majority of infants, are very frequent and are associated with substantial costs. Preventive strategies are based on vaccination against the most frequent agents, i.e., influenza virus and rotavirus, 21, 22 whereas specific therapies are lacking. The results of our study may open new perspectives in terms of prevention of frequent infections in infancy through functional nutrition in early infancy. However, the preventive effects on infections was not the only clinical effect we observed. The growth pattern differed between controls and children of the GOS/FOS group, with the latter showing a significant transient increase in weight and height at 3 and 6 months. Growth parameters of the two groups of children were similar at subsequent controls and at the end of the study. In contrast, the significant difference in length persisted, although it was of little absolute magnitude. It seems unlikely that the changes in growth parameters result from fewer infections, rather, a metabolic mechanism could be involved given the capacity of oligosaccharides to increase intestinal calcium absorption. 23 Whether prebiotics may induce a transient modification of a growth parameter in healthy children remains to be confirmed and does not beg substantial clinical implications. Our study has several limitations, the main of which being its open label design. This was discussed with the pediatricians involved in the study and it was concluded that a double blind design was not easily feasible. Both formulas were already commercially available and the introduction of blinding may have contributed in reducing the population size. It was eventually decided to adopt an observational protocol for this study. The relatively high dropouts, due to a long term observation, did not allow an intention to treat analysis, but the lack of difference in dropouts between the two groups and the post-experimental power analysis confirmed the statistical significance of our results.
Although many infant formulas enriched with prebiotics are commercially available, there is little proof of clinical advantages. The available data are largely of microbiological nature and based on the concept of making intestinal microecology of formula-fed infants similar to that of breast-fed infants. The European Society for Pediatric Gastroenterology, Hepatology and Nutrition has made a call for clinical trails on prebiotics in order to produce recommendations on their inclusion in infant formula. 24 Prebiotics are already included in infant formula, which stresses the need for clinical trials. When investigating the effects of functional nutrition in healthy subjects, the transfer from animal or experimental results to clinical application may be hampered by the high number of variables and confounding factors. Clinical research, may provide, through field studies, answers to the obvious question of whether investing money to improve infant formula is justified by clinically measurable benefits.
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